Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to $166000.0.

  • Dna X's Share-based Compensation fell 5549.6% to $166000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 682.24%. This contributed to the annual value of $1.5 million for FY2024, which is 193.85% up from last year.
  • Latest data reveals that Dna X reported Share-based Compensation of $166000.0 as of Q3 2025, which was down 5549.6% from $926000.0 recorded in Q2 2025.
  • In the past 5 years, Dna X's Share-based Compensation ranged from a high of $926000.0 in Q2 2025 and a low of $166000.0 during Q3 2025
  • Over the past 5 years, Dna X's median Share-based Compensation value was $325000.0 (recorded in 2021), while the average stood at $370473.7.
  • Per our database at Business Quant, Dna X's Share-based Compensation surged by 12350.88% in 2022 and then plummeted by 5549.6% in 2025.
  • Dna X's Share-based Compensation (Quarter) stood at $325000.0 in 2021, then increased by 27.69% to $415000.0 in 2022, then rose by 10.36% to $458000.0 in 2023, then fell by 22.27% to $356000.0 in 2024, then crashed by 53.37% to $166000.0 in 2025.
  • Its Share-based Compensation stands at $166000.0 for Q3 2025, versus $926000.0 for Q2 2025 and $290000.0 for Q1 2025.